Generated by GPT-5-mini| Science and Technology Committee (House of Commons) | |
|---|---|
| Name | Science and Technology Committee |
| Legislature | House of Commons of the United Kingdom |
| Type | Select committee |
| Established | 1967 |
| Jurisdiction | United Kingdom |
| Chair | Dame Andrea Jenkyns |
| Members | 11 |
| Parent organization | House of Commons |
Science and Technology Committee (House of Commons) is a select committee of the House of Commons of the United Kingdom tasked with oversight of scientific and technological matters affecting public policy. It examines policy implementation, holds inquiries, and produces reports influencing scrutiny of the Department for Science, Innovation and Technology, legacy departments such as the Department for Business, Energy and Industrial Strategy, and public bodies including UK Research and Innovation, the Met Office, and the National Physical Laboratory. The committee interacts with academic institutions, industry groups, and international bodies such as the European Commission, the Organisation for Economic Co-operation and Development, and the United Nations Educational, Scientific and Cultural Organization.
The committee traces its origins to advisory and select bodies convened in the post-war era, reflecting concerns raised by the Robbins Report and debates in the House of Commons during the 1960s about national research capacity. It was formally established amid reforms alongside committees like the Public Accounts Committee and the Environmental Audit Committee and has since evolved through successive Parliaments including the 1979 United Kingdom general election, the 1997 United Kingdom general election, the 2010 United Kingdom general election, and the 2019 United Kingdom general election. Its work has intersected with high-profile events such as the BSE crisis, the Fukushima Daiichi nuclear disaster, and the COVID-19 pandemic, prompting inquiries into scientific advice during emergencies, links with institutions like the Wellcome Trust, and coordination with bodies such as the Medical Research Council and the Biotechnology and Biological Sciences Research Council.
Membership is drawn from elected Members of Parliament allocated in proportion to party strength following the Leader of the House of Commons’ recommendations and approvals by the Committee of Selection (House of Commons). Chairs have included MPs with backgrounds in science or industry and have been elected under procedures established after reforms led by the House of Commons Commission and influenced by reforms advocated in the Wright Committee report. The committee typically comprises subject-specific specialists alongside MPs with portfolio interests connected to entities like the National Health Service (England) and research councils. It operates with staff such as clerks, specialist advisers, and forensic analysts who liaise with laboratories like the Francis Crick Institute and universities including University of Oxford, University of Cambridge, and Imperial College London.
The committee's remit includes examining the expenditure, administration and policy of departments and public bodies concerned with science and technology, including international obligations arising from treaties like the Treaty of Lisbon and collaborations with the European Space Agency. It can summon ministers, civil servants, and expert witnesses under powers analogous to those used by the Select Committee on Education, Skills and the Economy and may request documents from entities such as the National Institute for Health and Care Excellence and the Engineering and Physical Sciences Research Council. While it cannot compel implementation of recommendations, its findings have influenced legislation including Acts debated in the House of Commons, attachments to spending reviews, and frameworks like the National Science and Technology Council proposals.
The committee conducts topical and thematic inquiries, producing reports that draw on oral evidence from witnesses including chief executives of BT Group, scientists from Royal Society, executives from GlaxoSmithKline, and officials from Public Health England. Notable inquiries have covered topics such as research funding and the Horizon 2020 framework, the governance of novel technologies like artificial intelligence involving actors such as DeepMind and OpenAI, and the societal impacts of biotechnology linked to debates around the Human Fertilisation and Embryology Act. Its reports often recommend changes to funding mechanisms administered by UK Research and Innovation, reforms to peer review practiced by journals like Nature (journal) and The Lancet, and improvements in data governance referencing the General Data Protection Regulation and the Information Commissioner's Office. Findings have prompted parliamentary debates, ministerial statements, and responses from bodies including the National Institute for Health Research and the European Medicines Agency.
The committee has shaped policy by highlighting issues such as research reproducibility, industrial strategy, and the resilience of supply chains involving firms like Rolls-Royce Holdings and AstraZeneca. Its scrutiny during crises has been credited with improving transparency in interactions between scientists and policymakers during the COVID-19 pandemic and other emergencies, and with influencing investment priorities championed in industrial strategies linked to the Smart Specialisation Strategy. Critics argue the committee's influence is limited by the non-binding nature of its reports, political partisanship evident in questioning styles seen in exchanges involving MPs from parties such as the Conservative Party (UK), the Labour Party (UK), and the Scottish National Party, and by the pace at which scientific advice can be translated into legislation debated under timetabling set by the Minister for the Cabinet Office. Academic commentators from institutions like London School of Economics and University College London have also noted constraints arising from resource limits and the need for enhanced technical expertise to match rapidly evolving fields such as quantum computing linked to companies like IBM and advances in synthetic biology from centres like the Sainsbury Laboratory.